Oncology

In this interview, recorded at the end of the first day of PCOC®, Torrie Fields, senior program manager at Blue Shield of California, and Michael Kolodziej, MD, of ADVI Health, discuss the move to value-based care in oncology, what practices need to do to be successful, and the role of team-based care.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Bobby Green, MD, MSCE, senior vice president of clinical oncology at Flatiron Health, discusses analyzing patient data to improve the overall care delivery and its challenges involved with being so early in the process.

This week, the top managed care stories included the elimination of the Affordable Care Act's individual mandate; a new gene therapy for inherited vision loss that could cost $1 million; and a study found that social isolation can increase the risk of type 2 diabetes.

Key drug approvals; alcohol cancer link.

Articles on type 2 diabetes management, colon cancer screenings, and anti-rheumatic drug approvals topped the list.

Based on CMMI's year 1 feedback on OCM, it is clear that a lot of planning is needed and education is crucial, said Terrill Jordan, CEO, of Regional Cancer Care Associates.

For the most part, it’s well known that eating healthy and in moderation is more beneficial to our health. In 2017, there were a number of news stories that drove that knowledge home.

The FDA's 2013 accelerated approval of pertuzumab for neoadjuvant use was converted to full approval as part of treatment for patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer.

AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.

Contributors to AJMC.com delved into data to share their knowledge about important topics in managed care, and in 2017, these were the top 5 most-read articles they wrote and published on our online managed care network.

Nat Turner, co-founder and CEO of Flatiron Health, discusses how oncologists use data to assist them in meeting the requirements in new payment models.

Universal gene expression profiling of patients with stage II breast cancer resulted in outpatient savings of $11,000 (inclusive of testing costs) within 6 months of initiation of medical therapy.

As oncology practices transition to value-based care, they are challenged to take on more holistic responsibility for their patient. Fortunately, the examples of practices participating in CMS’ Oncology Care Model can offer valuable insight into the most impactful workflow changes providers can implement as they strive to achieve cost and quality improvements.

Coverage from the Community Oncology Alliance (COA)’s Payer Exchange Summit on Oncology Payment Reform, held October 23-24 in Tysons Corner, Virginia.

Coverage from the Community Oncology Alliance Payer Exchange Summit on Oncology Payment Reform, held October 23-24 in Tysons Corner, Virginia.

Increasing levels of CD8+ tumor-infiltrating lymphocytes are associated with prolonged survival in patients with high-grade serous ovarian cancer, endometrioid ovarian cancer, and mucinous ovarian cancer, according to a study published in JAMA Oncology.

Community oncologists face a challenge in getting patients into clinical trials, but new technology could help them get access to those trials, explained Tesh Khullar, senior vice president of provider solutions at Flatiron Health.

The FDA was busy in 2017, with a number of notable approvals, including the first chimeric antigen receptor T-cell treatment. In a session at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia, employees from the FDA presented data on 5 new drug approvals in leukemia and lymphoma in 2017.

A study published in JAMA Oncology found that prediagnosis inflammation was associated with at-diagnosis sarcopenia, and the combination of the 2 nearly doubled the risk of death in patients with nonmetastatic colorectal cancer. Because the 2 biomarkers are commonly collected and potentially modifiable, there is potential for clinical use in prognostication and guiding intervention.

The top 5 most-read news stories included clinical content, such as an FDA approval, and policy news, such as Medicare reimbursement coverage.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

In a session at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia, Brian Curtis, PhD, of the BloodCenter of Wisconsin Blood Research Institute, highlighted drugs other than chemotherapy that may cause neutropenia in patients.